Tissue Fixative Market Report: Trends, Forecast and Competitive Analysis to 2035

Tissue Fixative Market

The future of the global tissue fixative market looks promising with opportunities in the immunohistochemistry and immunocytochemistry markets. The global tissue fixative market is expected to reach an estimated $53 billion by 2035 from $34 billion in 2027 with a CAGR of 6.2% from 2027 to 2035. The major drivers for this market are the increasing demand for histopathology diagnostics testing, the rising adoption of advanced tissue preservation, and the growing investments in biomedical research laboratories.

• Lucintel forecasts that, within the type category, DEPC-free is expected to witness higher growth over the forecast period due to improved RNA integrity with DEPC-free fixatives.
• Within the application category, immunohistochemistry is expected to witness higher growth over the forecast period due to growing usage of IHC in diagnostics.
• In terms of regions, APAC is expected to witness the highest growth over the forecast period due to increasing diagnostic lab and research facilities.

Emerging Trends in Tissue Fixative Market

The market for tissue fixatives will experience changes between 2025 and 2027 as laborites considers trade-offs between worker safety, the environment, and time versus the accuracy of diagnoses. Demand will be driven by traditional histopathology as well as emerging areas like molecular pathology and biobanking. According to Lucintel, alternative fixatives and automation are other areas of rising demand.

• Safety: Methanol-based and glyoxal fixatives as well as lower formaldehyde fixatives are becoming more common as the limit set by OSHA for worker exposure to formaldehyde is 0.75 ppm over a period of 8 hours. In addition, a number of suppliers are promoting the use of fixatives in 2025-2027 that are dispensed in sealed systems in an attempt to further limit worker exposure.
• Automation: The use of automated systems to integrate specimen processing and tracking is expected to increase the demand for fixatives which are formulated to be compatible with automation and standardized in volume.
• Molecular Considerations: The demand will also be driven by the need to fix and preserve tissue for proteins and nucleic acids for the purpose of performing immunohistochemistry and next generation sequencing. The use of fixatives to reduce the trade-offs associated with preservation of tissue for diagnostics will be the focus of competition in the market.
• Sustainability: From 2025 to 2027, the range of environmental purchasing considerations is expected to encourage greater use of sustainable health care products and services. Limiting the number of shipments and used transport containers may be achieved through the use of more concentrated products. Within the same time frame, the focus of the health care sector on cost-effectiveness and sustainability is expected to cause many health care systems to expand their consideration of the chemical rather than the materials waste generated.
• Regional Supply Resilience: Tight integration of local manufacturing and the supply chain, in combination with dual supplier relationships and strategic inventory, will be aligned to meet the ongoing disruptions in the supply of chemicals and containers in the health care sector. The outcomes of tenders for health care products and services issued for the same time period are expected to encourage greater focus on the supply of health care products and services.

Within the time frame under review, the modernization of work processes will be the primary growth driver. Formaldehyde will remain the main molecular component of tissue fixatives. However, the component and supplier risk profiles will influence the purchases of health care products and services.

Recent Developments in the Tissue Fixative Market

The tissue fixative market is expected to grow in the coming years as pathology labs upgrade their facilities and volume of business increases. Between 2025 and 2027, the focus will be on reducing the risk associated with the use of formalin, introduction of automation in tissue processing, ensuring molecular compatibility of the processing and other supply chain requirements. According to Lucintel, the primary drivers of the market will be cancer diagnostics, biobanking and other activities conducted by pathology labs in hospitals.

• The Launch of Safety-related Products: In March 2025, Leica Biosystems introduced products under its HistoCore brand to improve tissue processing and formalin handling, thus optimizing laboratory workflows. As the cost of energy and other utilities increase, tissue processing laboratories will prefer using less formalin and formalin-based products.
• Automation and Integration of Digital Pathology: In 2025, Roche (via its acquired company PATHAI) furthered its automation and digital pathology efforts. Integration of digital pathology, automation and other edge computing technologies in the lab will require use of fixatives that preserved samples for long-periods of time and allowed extraction of biological signals.
• Compatibility with Molecular Fixatives: Histology and molecular diagnostics will continue to co-exist. Therefore, there will be a market for fixatives that help preserve nucleic acids. As the demand for molecular diagnostics and personalized medicine increases, formalin and other fixatives will be used in combination or in replacement of formalin.
• Supply and Capacity Changes: Disruptions in the supply of chemicals and logistics in 2025 once again delayed laboratory supplies. In the following years, supplier choices will be based on which can assure the uninterrupted supply of pathology supplies to hospitals.
• Formaldehyde: Restrictions on the use of formaldehyde by various EU and North American agencies in 2025, led to increased expenditures on low-formaldehyde and p-xylene-based tissue fixatives. While the use of closed systems resulted in a more secure working environment, the cost and the time required for system validation will slow the change.

The main driver of demand for tissue fixatives will continue to be the volume of specimens, and the speculative nature of the market will continue. However, the degree of sophistication of evaluating and comparing fixatives based on the total cost of ownership will increase. Suppliers that have sold and supported fixatives will continue to dominate the market. Niche suppliers will also be able to capture a small market by addressing the unmet need for safety and system compatibility.

Strategic Growth Opportunities in the Tissue Fixative Market

In the upcoming years, the tissue fixative market will experience growth due to a variety of reasons including increasing pathology volumes, laboratory automation, and concern for formalin emission. Lucintel has similar views on market trends and opportunities with emphasis on creating safer and more efficient methods and techniques for laboratory work, as well as facilitating molecular and other types of compatibility in various levels and methods, and decentralizing laboratory services.

• Molecular Compatibility: In the field of pathology and laboratory services, the demand for precision oncology and related tests will increase with time, especially with the growing need for biomarker tests and related services.
• Lower Toxicity: Due to occupational and environmental concerns, the demand for less toxic and better fixed and preservative agents will increase.
• Digital Pathology: There will be growing demand for fixatives that support and integrate automation in pathology services and testing.
• Research-grade Fixatives: Fixatives for research-grade sample preservation, e.g. for organoids and spatial biology, and for biobanks, are higher-margin products compared to those for conventional histology. In April 2025, the UK Biobank published imaging data for 100,000 study participants. Preserving samples to meet customers' requirements for various research applications will create a market for high-end fixatives and related services.
• New Laboratory Facilities in Emerging Countries: The oncology laboratories recently established in Latin America, the Middle East and Southeast Asia offer new business opportunities. Data from the 2025 National Cancer Registry of India estimated that over 1.5 million people are diagnosed with cancer each year. The availability of cancer-related products and services, and training, will predominantly determine the customers' preferences in the next five years.

Fixative formulations will remain the main basis for competition among manufacturers. However, suppliers should focus on regulatory and service-related aspects in addition to the formulations to be competitive in the market. Products that facilitate compliance to laboratory and regulatory requirements will have a competitive edge.

Tissue Fixative Market Drivers and Challenges

The tissue fixative market is impacted by various economic, regulatory, and technology-driven factors. Favorable market trends and the internationalization of the pathology and related biopharmaceutical and diagnostic industries have created greater worldwide demand. Improving automation and safer and better designs are market trends influencing fixative supply and specification. The Lucintel report cited the improvement of research facilities and the scale of the healthcare industry as positive marketing trends. The report identified a number of long-term threats including voluntary restriction of the use of certain chemicals, their transport and storage, and other environmental challenges. The tightening of market competition requires that companies balance the varying demands of marketing, service, user safety and protection, and environmental and safety concerns.

The factors responsible for driving this market include :

• Increased Customer Requirements: Rising volumes of biopsies and cancer screening and research, among other things, are creating greater market demand for formalin and other tissue fixatives. According to the World Health Organization, there was an estimated 20 million new cases of cancer in 2022. Given the projected trends in the population and other changes in the pathology field, it is expected that there will be increasing demand for the fixation of pathology specimens in the health sector.
• Improvements in Technology: More consistent automated methods for tissue fixation and processing, improved digital pathology, and the development of specimen types amenable to molecular testing, are all trends that are expected to diminish the need for human intervention and reduce the risk of introducing errors in the fixation and processing of specimens. The authorization by the U.S. Food and Drug Administration (FDA) in April 2025 of several digital pathology software applications created additional market demand for fixed specimens of consistent quality. The approval by the FDA is expected to accelerate the demand for specimens used in diagnostic tests.
• Quality and Safety Regulations: The adoption of quality and safety standards in the laboratories has led to the use of controlled fixation methods and the labeling of specimens in a manner that conforms to the standards. The enforcement of the classification and labeling of substances in the European Union in 2025 further facilitated the use of controlled fixation methods. The next three to five years will see an increased use of closed fixation systems in laboratory diagnostics.
• Sustainability Initiatives: The goals of many countries to improve their environmental records will also influence the choices made by laboratories. In 2025, several sustainability goals of the European Union were extended. In the next three to five years, there will be increased use of safer and more sustainable fixation systems.
• Manufacturing Efficiency: Streamlined chemical processing and bulk production enable raw material and resource optimization for the supply industry. Global Pharma spending is projected to reach over 1.7 trillion USD in 2025, creating a positive outlook for the research and manufacturing sectors. Raw material and logistic costs will increase and production will need to be localized. Significant variations in the cost and availability of raw materials will persist during this period, leading to the need for different supply networks to adequately serve various geographical markets.

The challenges facing this market include:

• Chemical Safety: There are stringent regulations regarding chemical safety. Costs associated with the use of formaldehyde and other chemicals in tissue fixation will increase due to greater enforcement of workplace safety. These costs will be further increased by the use of alternative fixatives. \
• Supply Chain: There are multiple suppliers for the raw materials and chemicals used in tissue fixation, but the supply is unpredictable due to geopolitical and international trade conditions. Over the next few years, raw materials will become even more expensive and difficult to acquire. These conditions will result in regional and national variations in supply and increased costs, leading to greater levels of inventory.
• Product Compatibility and Price: Other fixatives may be less expensive, but could require modification of lab protocols, staff training, and testing for compatibility with histology, IHC, and molecular tests. Laboratory reagent suppliers report validation and quality control have increased in 2025, which has increased their costs. It is expected that the diagnostic industry will prioritize safety and sustainability. However, clientele will compare the balance of these features to cost and performance of products. This will slow the introduction of new products.

Rising rates of disease and infection, coupled with increasing research, automation and regulatory mandates, will increase the need for diagnostic tests. This will stimulate growth in the tissue fixative market. The adoption of new diagnostic tests will depend on the joint consideration of numerous factors, including performance, cost and supplier capabilities to ensure safety, sustainability and reliability. If a supplier of tissue fixatives can gain a competitive edge by improving distribution, safety and reliability of specimen transportation, they will achieve a dominant market position. These factors will impact the diagnostics industry in the same manner they affect other industries and services.

List of Tissue Fixative Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies tissue fixative market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the tissue fixative market companies profiled in this report include-

• Liaoshiyuan Biomedical Technology
• Thermo Fisher Scientific
• Leica Biosystems
• Servicebio
• Saiguo Biotechnology

Tissue Fixative Market by Segment

The study includes a forecast for the global tissue fixative market by type, application, and region.

Tissue Fixative Market by Type [Value ($B) from 2019 to 2035]:

• DEPC-free
• DEPC-containing

Tissue Fixative Market by Application [Value ($B) from 2019 to 2035]:

• Immunohistochemistry
• Immunocytochemistry
• Others

Tissue Fixative Market by Region [Value ($B) from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Tissue Fixative Market

The tissue fixative market is experiencing changes due to automation of laboratories, improving pathology and intensifying regulations on the use of chemicals. Between 2025 and 2027, expectations will be to use validated workflows and lower exposure fixatives. Fixatives consumed by laboratories will be traced. Lucintel has reported that fixative suppliers will focus on developing products to meet the requirements of specific fields.

• United States: In September 2024, the medical diagnostics company Thermo Fisher Scientific completed the acquisition of Olink for 3.1 billion USD. In 2025, the budget of the National Cancer Institute (NCI) was approximately 7.1 billion USD. The NCI is expected to increase its emphasis on integrated sample processing. It is expected that fixatives used by automated diagnostics will increase in the next 3-5 years.
• China: In 2025, the State Council of China identified innovative biopharmaceuticals and cutting edge medical devices as strategic growth fields. In April 2025, the Roche Group opened a center for molecular diagnostics in Shanghai. It is expected that the continuous improvement and automation of diagnostic processes will also positively influence local fixative and consumables production.
• Germany: Merck spent €300 million (Oct. 2024) on its life-science business in Darmstadt. Beginning Sept. 2025, the EU's revised CLPH (Classification, Labelling and Packaging) rules apply to the marketing of all new and existing pharmaceuticals. There will likely be a preference for suppliers who have documented formulations, and safer and more reliable batch-to-batch performance.
• India: The Indian government allocated ₹1000 crore (Feb. 2025) to establish biologics manufacturing facilities and research infrastructure under the Biopharma SHAKTI program. With the increased governmental investments in cancer care, there will be more demand for pathology reagents and fixatives for transport and storage.
• Japan: In 2025, the Japanese government covered the cost for some patients to receive genomic tests for cancer, and Sysmex reported revenues of 478.5 billion yen for 2024 (May 2025). This positively impacted the company's stocks. There will be increased use of advanced diagnostics in pathology. Validation of fixative protocols, and quality control and assurance of tissue and specimen integrity prior to and during transport, will be critical.

Features of the Global Tissue Fixative Market

• Market Size Estimates: tissue fixative market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
• Segmentation Analysis: tissue fixative market size by type, application, and region in terms of value ($B).
• Regional Analysis: tissue fixative market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the tissue fixative market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the tissue fixative market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the tissue fixative market by type (depc-free and depc-containing), application (immunohistochemistry, immunocytochemistry, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?